Other headlines:Naviscan signs Korean distributor IT sales rise at Infinitt
Philips Healthcare has introduced to U.S. customers MammoDiagnost VU, a stand-alone mammography workstation that enables multivendor and multimodality image management and integration. Already available in Europe, the MammoDiagnost VU simplifies use by streamlining labor-intensive steps, automating breast tissue alignment for digital mammograms, and supporting personalized work lists.
Naviscan has signed a distribution agreement with the Hae Dong company to market and service breast-specific PET scanners in the Republic of South Korea. The first such unit capable of positron emission mammography will be installed at Seoul National University Hospital, where it will be available to physicians and researchers while awaiting Korean regulatory approval. The scanner uses PET technology to produce tomographic images that visualize breast tumors down to 2 mm, which is about the width of a grain of rice. About the size of an x-ray mammography unit, the PET scanner uses gentle breast immobilization to reduce motion artifact and improve image resolution.
Web-based IT vendor Infinitt North America is on track for a record year. The company reports that product sales in the U.S. during the first two quarters of 2009 have exceeded those of any two consecutive quarters in the firm's history. Its performance is all the more significant, according to company execs, given tight budgets at hospitals in this country and uncertainty about the future direction of healthcare. Infinitt offers web-based RIS and PACS products that support radiology, cardiology, mammography, and advanced visualization on a single common database.
AI-Initiated Recalls After Screening Mammography Demonstrate Higher PPV for Breast Cancer
March 18th 2025While recalls initiated by one of two reviewing radiologists after screening mammography were nearly 10 percent higher than recalls initiated by an AI software, the AI-initiated recalls had an 85 percent higher positive predictive value for breast cancer, according to a new study.